Serono

Serono. Serono was a pioneering global biotechnology company, originally founded in Italy and later headquartered in Switzerland, that specialized in developing treatments for fertility, growth, and autoimmune disorders. For much of the 20th century, it was the world's largest biotechnology firm by revenue, renowned for its innovative work in reproductive medicine and neurology. The company's independent history concluded when it was acquired by the German pharmaceutical giant Merck KGaA in a landmark deal, forming the foundation for Merck Serono.

History

The company's origins trace back to 1906, when pharmacist Cesare Serono established a small laboratory in Rome. Initially focused on producing pharmaceutical extracts, the firm gained prominence under the leadership of Serono's son-in-law, Fabio Bertarelli. A pivotal moment came in the 1970s with the development and global launch of urofollitropin, a purified fertility hormone derived from human urine, which revolutionized assisted reproduction. Under the leadership of Ernesto Bertarelli, grandson of the founder, the company transformed into a fully integrated biopharmaceutical powerhouse, relocating its corporate headquarters to Geneva in the late 1990s. This period was marked by significant expansion, including the acquisition of the American biotech firm Ares-Serono and the establishment of a major research presence in the United States.

Products and research

Serono's portfolio was built on several blockbuster therapies that defined entire treatment categories. Its flagship fertility product line, including Gonal-f, a recombinant version of follicle-stimulating hormone, became the global standard for in vitro fertilisation treatments. In neurology, the company developed Rebif, a leading therapy for relapsing forms of multiple sclerosis that competed directly with products from Biogen and Teva Pharmaceutical Industries. Another cornerstone was Serostim, a growth hormone treatment for HIV-associated wasting. The company's substantial research and development efforts were conducted at major centers in Switzerland, Italy, and Massachusetts, focusing on areas like endocrinology, immunology, and oncology.

Corporate affairs

As a publicly traded company, Serono was listed on the SIX Swiss Exchange and the New York Stock Exchange, reflecting its significant international investor base. The Bertarelli family, through their holding company, maintained a controlling interest for decades. In 2006, after a strategic review, the family accepted a takeover offer from Merck KGaA of Darmstadt, Germany, in a transaction valued at approximately 10.6 billion euros. This acquisition, one of the largest in European biotech history, did not include Serono's lucrative Merck Serono division, which was later spun off. The integration process led to the consolidation of research sites and a restructuring of the global commercial operations.

Legacy and impact

Serono's legacy is profound in the fields of reproductive medicine and biotechnology commercialization. Its innovations provided the foundation for modern fertility treatments, impacting millions of families worldwide. The company also played a crucial role in establishing Switzerland as a major hub for life sciences. The integrated entity Merck Serono became a key division within Merck KGaA, although the Serono name was eventually phased out from the corporate branding in 2015. The Bertarelli family channeled a portion of the sale proceeds into significant philanthropic ventures, including the Bertarelli Foundation, which supports marine conservation and neuroscience research. Serono's story remains a seminal case study in the evolution of a family-owned apothecary into a global biotech leader. Category:Biotechnology companies Category:Pharmaceutical companies of Switzerland Category:Companies established in 1906 Category:Companies disestablished in 2007